HKD 7.66
(-1.42%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 31.18 Million USD | 127.88% |
2022 | -115.5 Million USD | 11.85% |
2021 | -130.84 Million USD | 54.96% |
2020 | -290.91 Million USD | -362.57% |
2019 | -62.89 Million USD | -90.47% |
2018 | -33.01 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 496 Thousand USD | -94.59% |
2024 Q2 | 496 Thousand USD | 0.0% |
2023 Q4 | 9.17 Million USD | 0.0% |
2023 Q2 | 2.89 Million USD | 0.0% |
2023 Q3 | 9.17 Million USD | 217.14% |
2023 FY | - USD | 127.88% |
2023 Q1 | 2.89 Million USD | 111.75% |
2022 FY | - USD | 11.85% |
2022 Q4 | -24.61 Million USD | 0.0% |
2022 Q3 | -24.61 Million USD | 27.44% |
2022 Q2 | -33.92 Million USD | 0.0% |
2022 Q1 | -33.92 Million USD | 24.39% |
2021 Q4 | -44.86 Million USD | 0.0% |
2021 Q3 | -44.86 Million USD | -84.47% |
2021 Q1 | -24.32 Million USD | 31.73% |
2021 FY | - USD | 54.96% |
2021 Q2 | -24.32 Million USD | 0.0% |
2020 Q4 | -35.62 Million USD | 0.0% |
2020 Q2 | -6.18 Million USD | 0.0% |
2020 Q1 | -6.18 Million USD | 38.49% |
2020 FY | - USD | -362.57% |
2020 Q3 | -35.62 Million USD | -475.56% |
2019 Q3 | -10.06 Million USD | 36.97% |
2019 FY | - USD | -90.47% |
2019 Q4 | -10.06 Million USD | 0.0% |
2019 Q2 | -15.96 Million USD | 0.0% |
2019 Q1 | -15.96 Million USD | 0.0% |
2018 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Uni-Bio Science Group Limited | 91.23 Million HKD | 65.819% |
CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 93.594% |